Allogeneic cell therapies, and even more so iPSC derived therapies, have the potential to reach hundreds, if not thousands of patients. However, to be able meet demand, the manufacturing process has to be reliably scaled up with no significant impact to product quality. Fate is exploring two strategies for scale up: volumetric scaling and culture intensification. Here we present preliminary results from feasibility studies demonstrating the impact of both strategies on our drug substance expansion process. Both strategies appear to be feasible per the growth kinetics and phenotype at harvest.